These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1477 related articles for article (PubMed ID: 15753383)
1. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383 [TBL] [Abstract][Full Text] [Related]
2. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
3. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Ghosh PM; Malik SN; Bedolla RG; Wang Y; Mikhailova M; Prihoda TJ; Troyer DA; Kreisberg JI Endocr Relat Cancer; 2005 Mar; 12(1):119-34. PubMed ID: 15788644 [TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S; Agoulnik IU; Weigel NL Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350 [TBL] [Abstract][Full Text] [Related]
5. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959 [TBL] [Abstract][Full Text] [Related]
6. 17beta-estradiol up-regulates the insulin-like growth factor receptor through a nongenotropic pathway in prostate cancer cells. Pandini G; Genua M; Frasca F; Squatrito S; Vigneri R; Belfiore A Cancer Res; 2007 Sep; 67(18):8932-41. PubMed ID: 17875736 [TBL] [Abstract][Full Text] [Related]
7. Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Kokontis JM; Hsu S; Chuu CP; Dang M; Fukuchi J; Hiipakka RA; Liao S Prostate; 2005 Dec; 65(4):287-98. PubMed ID: 16015608 [TBL] [Abstract][Full Text] [Related]
8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349 [TBL] [Abstract][Full Text] [Related]
9. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471 [TBL] [Abstract][Full Text] [Related]
10. Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Gnanapragasam VJ; Robson CN; Neal DE; Leung HY Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757 [TBL] [Abstract][Full Text] [Related]
11. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A. Desiniotis A; Schäfer G; Klocker H; Eder IE Int J Cancer; 2010 Feb; 126(3):775-89. PubMed ID: 19653278 [TBL] [Abstract][Full Text] [Related]
12. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Zhao XY; Ly LH; Peehl DM; Feldman D Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780 [TBL] [Abstract][Full Text] [Related]
13. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446 [TBL] [Abstract][Full Text] [Related]
14. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082 [TBL] [Abstract][Full Text] [Related]
16. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide. Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237 [TBL] [Abstract][Full Text] [Related]
17. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells. Genua M; Pandini G; Sisci D; Castoria G; Maggiolini M; Vigneri R; Belfiore A Cancer Res; 2009 Sep; 69(18):7270-7. PubMed ID: 19738069 [TBL] [Abstract][Full Text] [Related]
18. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440 [TBL] [Abstract][Full Text] [Related]
19. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
20. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]